Summary:
Lucid Diagnostics and Hoag have launched a comprehensive esophageal precancer screening program using the non-endoscopic EsoGuard DNA test to enhance early detection and prevention of esophageal cancer.
Takeaways:
- Hoag will integrate EsoGuard testing across its digestive health, primary care, and concierge medicine programs.
- The goal is to identify at-risk patients early using a quick, non-invasive 3-minute test.
- This partnership marks a key step in expanding EsoGuard’s availability through large healthcare systems.
Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., has announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics’ EsoGuard Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, primary care, and concierge medicine programs…